Covered recipient · General Payments record
JOSIE L LOPEZ
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$997.37
- Reported across 49 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $334.50 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $80.18 | 5 |
| ABBVIE INC. | $58.24 | 2 |
| Lilly USA, LLC | $48.28 | 3 |
| Amgen Inc. | $41.14 | 2 |
| DEXCOM, INC. | $40.83 | 2 |
| Lundbeck LLC | $25.16 | 1 |
| IBSA Pharma Inc. | $24.56 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $16.11 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $34.22 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105132515 | CMS |
| ABBVIE INC. | $24.02 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105132517 | CMS |
| Amgen Inc. | $20.24 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111637480 | CMS |
| Amgen Inc. | $20.90 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111637478 | CMS |
| Dexcom, Inc. | $20.14 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153311862 | CMS |
| Dexcom, Inc. | $20.69 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153311864 | CMS |
| IBSA Pharma Inc. | $24.56 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142974325 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $16.11 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146774154 | CMS |
| Lilly USA, LLC | $13.41 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135087248 | CMS |
| Lilly USA, LLC | $17.77 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135088679 | CMS |
| Lilly USA, LLC | $17.10 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135107309 | CMS |
| Lundbeck LLC | $25.16 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145951353 | CMS |
| Novo Nordisk Inc | $13.20 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097566157 | CMS |
| Novo Nordisk Inc | $14.52 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097275896 | CMS |
| Novo Nordisk Inc | $21.30 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096885927 | CMS |
| Novo Nordisk Inc | $17.90 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097276213 | CMS |
| Novo Nordisk Inc | $13.26 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097129691 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.